YAP1 and age-related macular degeneration: Verteporfin is therefore a positive candidate for reprofiling as in addition to its role as a YAP inhibitor, it is used clinically to treat neovascular age-related macular degeneration (AMD)38 and has previously been shown in vitro to reduce cancer growth33,39,40.